CBDB(CAS 60113-11-3)is an analytical reference standard categorized as a phytocannabinoid. CBDB has been found in strains of Cannabis and hemp. CBDB is considered an impurity in commercial extractions of cannabidiol (CBD) from hemp. This product is intended for research and forensic applications.
Name :
CBDBCAS No. :
60113-11-3MF :
C20H28O2MW :
300.44Purity :
98%Appearance :
White to off-white crystalline solidStorage Condition :
Stable under normal conditions but sensitive to strong oxidizing agents and lightBasic Information
Chemical Name: CBDB
Synonyms:Cannabidibutol;Cannabidiol-C4:CBD-C4
CAS Number: 60113-11-3
Molecular Formula: C20H28O2
Molecular Weight: 300.44 g/mol
Physical and Chemical Properties
Appearance: White to off-white crystalline solid .
Boiling Point: 451.7±45.0 °C(Predicted)
Density: 1.035±0.06 g/cm3(Predicted)
pka:9.61±0.45(Predicted)
Solubility:
DMF: 50 mg/ml
DMSO: 60 mg/ml
DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml
Ethanol: 35 mg/ml
Stability: Stable under normal conditions but sensitive to strong oxidizing agents and light.
SMILES:CC1=C[C@@H](C2=C(O)C=C(CCCC)C=C2O)[C@H](C(C)=C)CC1
InChi Code:InChI=1S/C20H28O2/c1-5-6-7-15-11-18(21)20(19(22)12-15)17-10-14(4)8-9-16(17)13(2)3/h10-12,16-17,21-22H,2,5-9H2,1,3-4H3/t16-,17+/m0/s1
InChi Key:WBRXESQKGXYDOL-DLBZAZTESA-N
Key Applications
Intermediate for synthesizing brominated biphenyl derivatives and heterocyclic compounds.
Potential precursor for pharmaceuticals (e.g., kinase inhibitors) or agrochemicals.
Functional monomer in polymer synthesis (e.g., UV-stable resins).
Catalyst or ligand in coordination chemistry.
Safety and Handling
Hazard Classification:
Risk Statements:
R36/37/38: Irritating to eyes, respiratory system, and skin.
R50/53: Very toxic to aquatic life with long-lasting effects.
Precautionary Measures:
Use PPE (gloves, goggles, lab coat).
Handle in a fume hood; avoid inhalation or contact with skin/eyes.
Dispose of waste according to hazardous chemical protocols.
Synthesis Methods
Primary Routes:
Bromination of 4-Biphenylcarboxylic Acid:
React 4-biphenylcarboxylic acid with bromine (Br₂) in the presence of a Lewis acid catalyst (e.g., FeBr₃).
Cyanation Followed by Hydrolysis:
Introduce a cyano group via nucleophilic aromatic substitution, followed by hydrolysis to the carboxylic acid.
Purification: Recrystallization from ethanol or sublimation under vacuum.
FAQ
Q: How does CBDB compare to similar compounds in terms of efficacy and safety?
A: CBDB stands out as a targeted 5α-reductase inhibitor with fewer psychoactive risks compared to cannabinoids like THC. However, its safety and efficacy lag behind optimized derivatives like KLS-13019, which balances potency and reduced toxicity. Future research should prioritize structural modifications (e.g., esterification) to enhance bioavailability and reduce irritation risks.
Q: Are there any clinical trials or in vivo studies currently underway for CBDB?
A: CBDB is still in the preclinical research stage at present. Its core challenges lie in formulation optimization and mechanism deepening. In the future, it is necessary to accelerate clinical transformation through industry-university-research cooperation, especially in the fields of prostate diseases and cancer treatment, where there is potential for breakthroughs.
Q: What specific structural modifications could improve CBDB's bioavailability while maintaining its efficacy?
A: The most promising strategies for CBDB involve side chain truncation, phenolic functionalization, and nanocarrier encapsulation. These modifications enhance solubility and reduce metabolism while preserving 5α-reductase inhibition and neuroprotective activity. Future studies should prioritize in vivovalidation of these modifications to balance pharmacokinetics and pharmacodynamics.
CBDB(CAS 60113-11-3)is an analytical reference standard categorized as a phytocannabinoid. CBDB has been found in strains of Cannabis and hemp. CBDB is considered an impurity in commercial extractions of cannabidiol (CBD) from hemp. This product is intended for research and forensic applications.
Details
Cannabidihexol (CAS 2552798-21-5) is a novel phytocannabinoid derivative with promising analgesic and neuroprotective properties. While its pharmacological profile is promising, further research is needed to validate its therapeutic potential and optimize its pharmacokinetics.
Details
Cannabidiphorol (CAS 55824-13-0) is a novel phytocannabinoid derivative with promising analgesic and neuroprotective properties. Its high lipophilicity and structural complexity present challenges in drug development but also offer opportunities for targeted therapeutic applications.
Details
CBGB (CAS 2468125-69-9) represents a novel organic compound with potential applications in pharmaceuticals or materials science. Its structural complexity and lack of explicit data highlight the need for further experimental characterization and regulatory review.
Details
CBGAQ (CAS 2442482-70-2) is a key synthetic intermediate featuring a reactive diene core and a carboxylic acid functional group. It is primarily used in the synthesis of complex organic molecules, including cannabinoid precursors and other bioactive compounds.
Details
Cannabielsoin(CBE) (CAS 52025-76-0) is a phytocannabinoid derivative with potential analgesic and neuroprotective applications. Its structural complexity and lipophilicity present challenges in drug development but also offer opportunities for targeted therapeutic formulations.
Details
Contact Us
1st Floor, No. 477, Huancheng West Road, Nanqiao Town, Fengxian District, Shanghai,China
sales@qxscientific.com
+86 -13701740203
IPv6 Network Supported |
Sitemap |
XML |
Blog |
Privacy Policy
Leave A Message
Scan to Wechat/Whatsapp :
English
English
Español
Português
